07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Damage induced noncoding (DINO)

Other INDICATION: Poisoning Cell culture and mouse studies suggest inhibiting DINO could help treat chemotherapy- and radiation-induced DNA damage and death. In mouse embryonic fibroblasts pretreated with the DNA-damaging generic chemotherapy doxorubicin, knockout of DINO decreased cell...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Cancer diagnostics measuring the mechanical properties of cells Human tissue studies suggest measuring the mechanical properties of...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Dynavax management update

Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif.   Business: Inflammation, Infectious, Autoimmune   Departing: Tyler Martin as president, effective May 31   Hired: Eddie Gray as CEO and a director, formerly president of pharmaceuticals Europe at GlaxoSmithKline plc;...
07:00 , May 14, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) was up $3.77 (146%) to $6.36 last week, including a $2.70 (74%) jump on Friday after an FDA panel voted 18-4, with one abstention, that the benefit-risk profile for lorcaserin...
01:24 , May 9, 2012 |  BC Extra  |  Company News

Dynavax proposes follow-on, begins search for new CEO

Dynavax Technologies Corp. (NASDAQ:DVAX) announced a proposed follow-on late Tuesday and said it plans to add experienced commercial leadership to its management team, including a new CEO. After a recommendation from CEO Dino Dina, Dynavax's...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

Heplisav's salvation

Dynavax Technologies Corp. could soon reap the rewards of persevering with its Heplisav HBV program. It has Phase III data in hand showing superiority to standard of care, a BLA submission planned for year end...
08:00 , Nov 16, 2009 |  BioCentury  |  Finance

Ebb & Flow

Although the terms of the acquisition of BioTrove Inc. by Life Technologies Corp. (NASDAQ:LIFE) haven't been undisclosed, the transaction could result in a more than 10X return over the next 12 months, according to investor...
08:00 , Nov 5, 2007 |  BioCentury  |  Strategy

Momentum builder

Instead of taking on vaccine powerhouses Merck & Co. Inc. and GlaxoSmithKline plc, both of which market hepatitis B vaccines, Dynavax Technologies Corp. thought it would be more beneficial to join forces to promote its...
07:00 , May 7, 2007 |  BC Week In Review  |  Company News

diaDexus management update

diaDexus Inc., South San Francisco, Calif.   Business: Diagnostic   Hired: David Foster as CFO and EVP, formerly CFO of Argonaut Technologies Inc.; and Dino Alfano as EVP of sales and marketing, formerly president of ...
07:00 , Aug 14, 2006 |  BioCentury  |  Product Development

Continuum conundrum

One of the hopes of researchers developing immunostimulatory agents such as those targeting toll-like receptors, CD28 and CTLA-4 has been to generate specific and potent immune responses without the side effects of older approaches like...